Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Funding boost for GSK’s Open Innovation Research

Published: Wednesday, May 08, 2013
Last Updated: Wednesday, May 08, 2013
Bookmark and Share
GSK announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing new treatments for diseases of the developing world.

The funding will move early-stage research to the next level, to find new medicines for diseases such as TB, malaria, Leishmaniasis and sleeping sickness. Scientists from around the world will work in collaboration with GSK drug discovery experts at its facility in Tres Cantos, Madrid – where GSK’s work researching diseases of the developing world is focused – with the overarching goal of developing two high-quality experimental drugs over the next five years.

GSK has been committed to an open approach to discovering new treatments for diseases of the developing world since 2010, when it created its Open Lab. Here, external researchers can work on their early stage research alongside GSK scientists at a dedicated facility at Tres Cantos, Madrid, benefiting from GSK facilities, resources and knowledge to help them advance their own research projects. Diseases of the developing world affect millions of people and yet R&D is struggling, due to the complexity of the science and low return on investment. To help address this, GSK’s Tres Cantos facility is intended to be an engine room of scientific innovation, stimulating more R&D into diseases that affect the world’s poorest people.   Based on the belief that transparency, openness and collaboration are key to igniting research in to these diseases, the Open Lab has, since its establishment, hosted 27 external researchers, who have worked alongside and been supported by GSK scientists on early-stage projects to identify compounds that are active against these diseases.

The £5m Wellcome Trust funding announced today will be used to take this open approach a significant step further, tackling the next phase of drug development with the aim of turning promising active compounds into high quality experimental drugs. The funding will provide the opportunity to progress the most promising projects underway by independent scientists at the Open Lab and from GSK’s own research portfolio. Innovative research that has come about using the GSK malaria and TB compound collections – which have been made freely available and publically accessible by GSK – also have the potential to benefit from the Wellcome Trust funding.

Dr Nick Cammack, Head of GSK’s Tres Cantos Medicines Development Campus, which houses the Open Lab  said: “This support highlights a growing recognition that collaborative and open research is the key to tackling these devastating diseases. Since adopting an open approach to discovering new medicines for developing world diseases, we’ve hosted some of the world’s brightest academic scientists at Tres Cantos. The fusion of their academic excellence with GSK expertise has yielded some really exciting research projects. This tremendous show of support from the Wellcome Trust means we now have the potential to start driving these projects further towards finding new medicines.”

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: “Academic researchers are making incredible progress in our understanding of neglected diseases yet we’ve still got a bottle neck when it comes to the development of new drugs. Taking a more collaborative approach, as GSK have through their open lab, will see these advances reap the full benefit of the industry’s commercial expertise to give us the best chance of securing new treatments for these devastating diseases.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Publishes Promising New Data for COPD Drug
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice.
Wednesday, May 25, 2016
Zymeworks, GSK Enter Second Strategic Collaboration
Zymeworks has announced that it has entered into a new licensing agreement with GSK for the research, development, and commercialization of novel bi-specific antibodies enabled using Zymeworks’ Azymetric™ drug discovery platform.
Wednesday, April 27, 2016
SBP, GSK Create New Center for Translational Neuroscience
Academic-industry alliance seeks to find and validate new targets for drug development.
Thursday, April 21, 2016
GSK Won't Seek Drug Patents in Poor Countries
Company expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
Friday, April 01, 2016
VBI, GSK Collaborate
VBI Vaccines has entered into a research collaboration with GlaxoSmithKline Biologicals SA (“GSK”) to evaluate VBI’s LPV™ Platform. VBI’s LPV Platform is a proprietary formulation and process that enables the development of vaccines and biologics with improved stability and preserved potency.
Wednesday, February 10, 2016
GSK Strengthens HIV Drug Pipeline
Two transactions further strengthen HIV pipeline and outlook.
Tuesday, December 22, 2015
GSK Receives Positive CHMP Opinion in Europe for Asthma Therapeutic
GlaxoSmithKline has announced that the CHMP of the EMA has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Monday, September 28, 2015
GSK, Francis Crick Institute Collaborate
This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
Monday, July 20, 2015
GSK’s 2015 Discovery Fast Track Challenge
Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US.
Wednesday, March 25, 2015
GSK to Invest £200 Million in UK Manufacturing
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
Thursday, December 12, 2013
GSK and the Bill & Melinda Gates Foundation to Accelerate Research into Vaccines
The joint initiative will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration.
Wednesday, October 30, 2013
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
GSK and Save the Children Partner to Help Africa
Currently, nearly 7 million children under five die every year from preventable diseases.
Friday, May 10, 2013
GSK Gives Update on Plans to Share Detailed Clinical Trial Data
New online system will enable researchers to request access to patient level data from GSK clinical trials to help further scientific understanding and improve patient care.
Wednesday, May 08, 2013
GSK Provides Update on Corporate Responsibility Commitments in 2011 Report
Company publishes its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Monday, April 16, 2012
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos